# A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

> **NCT02338843** · PHASE3 · COMPLETED · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 344 (actual)

## Conditions studied

- Catecholamine-resistant Hypotension (CRH)
- Distributive Shock
- High Output Shock
- Sepsis

## Interventions

- **DRUG:** LJPC-501
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02338843
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-12-01
- **Final completion:** 2017-02-18
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02338843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02338843, "A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02338843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*